Literature DB >> 12714620

Periductal area as the primary site for T-cell activation in lacrimal gland chronic graft-versus-host disease.

Yoko Ogawa1, Masataka Kuwana, Kazuto Yamazaki, Yukihiko Mashima, Masakazu Yamada, Takehiko Mori, Shinichiro Okamoto, Yoshihisa Oguchi, Yutaka Kawakami.   

Abstract

PURPOSE: To examine immune processes in the lacrimal gland of patients with chronic graft-versus-host disease (cGVHD) by evaluating the expression of surface molecules associated with T-cell activation.
METHODS: Antibodies to CD4, CD8, CD34, CD40, CD54, CD80, CD86, CD154, and HLA-DR were used for immunohistochemical analysis of lacrimal gland biopsy specimens obtained from nine patients with cGVHD and five with Sjögren's syndrome (SS). The regions of interest were further assessed by transmission electron microscopy.
RESULTS: CD4(+) and CD8(+) T cells were mainly detected in the periductal areas of the glands of patients with cGVHD, but were distributed throughout the acinar areas in patients with SS. In the periductal areas of patients with cGVHD, a subpopulation of CD4(+) and CD8(+) T cells expressed the activation marker CD154. In addition, CD4(+) and CD8(+) T cells were colocalized with mononuclear infiltrates and stromal fibroblasts expressing the full component of surface molecules necessary for antigen presentation, including HLA-DR, CD54, CD40, CD80, and CD86. Electron microscopy revealed activated fibroblasts that embraced lymphocytes and macrophages with their processes. Also, there were more CD8(+) T cells in the glandular epithelia of patients with cGVHD than in those with SS. Intraepithelial T cells were attached to epithelial cells by several primitive contacts and colocalized with dead cells.
CONCLUSIONS: The results strongly suggest that CD4(+) and CD8(+) T cells in the lacrimal glands of patients with cGVHD are primarily activated in the periductal area through antigenic stimulation by potent antigen-presenting cells and stromal fibroblasts, and exert various effector functions, including cytotoxic effects on glandular epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12714620     DOI: 10.1167/iovs.02-0699

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  28 in total

Review 1.  Effect of inflammation on lacrimal gland function.

Authors:  Driss Zoukhri
Journal:  Exp Eye Res       Date:  2005-11-23       Impact factor: 3.467

2.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Authors:  Howard M Shulman; Diana M Cardona; Joel K Greenson; Sangeeta Hingorani; Thomas Horn; Elisabeth Huber; Andreas Kreft; Thomas Longerich; Thomas Morton; David Myerson; Victor G Prieto; Avi Rosenberg; Nathaniel Treister; Kay Washington; Mirjana Ziemer; Steven Z Pavletic; Stephanie J Lee; Mary E D Flowers; Kirk R Schultz; Madan Jagasia; Paul J Martin; Georgia B Vogelsang; David E Kleiner
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-29       Impact factor: 5.742

3.  Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease.

Authors:  Jianyu Weng; Chang He; Peilong Lai; Chenwei Luo; Rong Guo; Suijing Wu; Suxia Geng; Andy Xiangpeng; Xialin Liu; Xin Du
Journal:  Mol Ther       Date:  2012-10-16       Impact factor: 11.454

Review 4.  Dry eye disease: an immune-mediated ocular surface disorder.

Authors:  William Stevenson; Sunil K Chauhan; Reza Dana
Journal:  Arch Ophthalmol       Date:  2012-01

5.  Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice.

Authors:  Lauren M Curtis; Manuel B Datiles; Seth M Steinberg; Sandra A Mitchell; Rachel J Bishop; Edward W Cowen; Jacqueline Mays; John M McCarty; Zoya Kuzmina; Filip Pirsl; Daniel H Fowler; Ronald E Gress; Steven Z Pavletic
Journal:  Haematologica       Date:  2015-06-18       Impact factor: 9.941

Review 6.  Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.

Authors:  Yoshihiro Inamoto; Nuria Valdés-Sanz; Yoko Ogawa; Monica Alves; Luigi Berchicci; John Galvin; Hildegard Greinix; Gregory A Hale; Biljana Horn; Debra Kelly; Hien Liu; Scott Rowley; Helene Schoemans; Ami Shah; Maria Teresa Lupo Stanghellini; Vaibhav Agrawal; Ibrahim Ahmed; Asim Ali; Neel Bhatt; Michael Byrne; Saurabh Chhabra; Zachariah DeFilipp; Kristina Fahnehjelm; Nosha Farhadfar; Erich Horn; Catherine Lee; Sunita Nathan; Olaf Penack; Pinki Prasad; Seth Rotz; Alicia Rovó; Jean Yared; Steven Pavletic; Grzegorz W Basak; Minoo Battiwalla; Rafael Duarte; Bipin N Savani; Mary E D Flowers; Bronwen E Shaw; Igor Petriček
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-24       Impact factor: 5.742

7.  Dry Eye Disease Incidence Associated with Chronic Graft-Host Disease: Nonconcurrent Cohort Study (An American Ophthalmological Society Thesis).

Authors:  Shahzad I Mian; Paola De la Parra-Colín; Rafael De Melo-Franco; Christopher Johnson; Tonatiuh Barrientos-Gutierrez
Journal:  Trans Am Ophthalmol Soc       Date:  2015-09

8.  Treatment of refractory dry eye associated with graft versus host disease with 0.03% tacrolimus eyedrops.

Authors:  Empar Sanz-Marco; Patricia Udaondo; Salvador García-Delpech; Amparo Vazquez; Manuel Diaz-Llopis
Journal:  J Ocul Pharmacol Ther       Date:  2013-08-15       Impact factor: 2.671

9.  Suppression of lymphocyte proliferation and regulation of dendritic cell phenotype by soluble mediators from rat lacrimal epithelial cells.

Authors:  M de Saint Jean; T Nakamura; Y Wang; M D Trousdale; J E Schechter; A K Mircheff
Journal:  Scand J Immunol       Date:  2009-07       Impact factor: 3.487

10.  Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.

Authors:  Yoshihiro Inamoto; Nuria Valdés-Sanz; Igor Petriček; Yoko Ogawa; Monica Alves; Luigi Berchicci; John Galvin; Hildegard Greinix; Gregory A Hale; Biljana Horn; Debra Kelly; Hien Liu; Scott Rowley; Helene Schoemans; Ami Shah; Maria Teresa Lupo Stanghellini; Vaibhav Agrawal; Ibrahim Ahmed; Asim Ali; Neel Bhatt; Michael Byrne; Saurabh Chhabra; Zack DeFilipp; Kristina Fahnehjelm; Nosha Farhadfar; Erich Horn; Catherine Lee; Sunita Nathan; Olaf Penack; Pinki Prasad; Seth Rotz; Alicia Rovó; Jean Yared; Steven Pavletic; Grzegorz W Basak; Minoo Battiwalla; Rafael Duarte; Bipin N Savani; Mary E D Flowers; Bronwen E Shaw
Journal:  Bone Marrow Transplant       Date:  2018-12-07       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.